PharmaCyte Biotech, Inc. (PMCB) Options Statistics & Positioning

Max pain sits at $2.5 and the put/call open interest ratio is 0.00. Statistics are computed by OptiView from delayed OPRA options data and refresh every trading day.

Data as of Aug 24, 2026, 3:55 PM ET · OPRA data 15 minutes delayed · For information only — not investment advice.

Last close
$0.52
52-week range
$0.52 – $1.23
IV rank
100 / 100
High
Put/call OI
0.00
Call-heavy
Max pain
$2.5
↑ 378.5% above close
Next earnings
Sep 14, 2026

Most Active PMCB Contracts

ContractExpirationDTELastIVVolume
PMCB $2.5 call Apr 16, 2027 235d $0.05 17
See all active PMCB contracts →

Explore PMCB Options Statistics

Upcoming Earnings

PMCB's next expected earnings date is Sep 14, 2026.

Explore the payoff profile of option on PMCB for free

Build multi-leg PMCB strategies, visualize payoffs, and scan the full US options universe with OptiView.

PMCB Options FAQ

When is PMCB's next earnings date?

PMCB's next expected earnings date is Sep 14, 2026.

How often is PMCB options data on this page updated?

All PMCB statistics on this page are computed by OptiView from delayed OPRA options data and refresh every trading day after the session close.

Where can I see PMCB max pain, open interest, and implied volatility in detail?

OptiView publishes dedicated PMCB pages for implied volatility, max pain, open interest, gamma exposure, options volume, and the most active contracts — each with charts, history, and a plain-English explanation of what the numbers mean.

Methodology. IV rank compares the current 30-day at-the-money implied volatility with its highest and lowest values over the past 52 weeks. Max pain is the strike that minimizes the total payout to option holders at expiration. The call and put walls are the strikes carrying the largest call and put open interest across all expirations. Net gamma exposure (GEX) is measured from the dealer perspective. All statistics are derived from delayed OPRA options data.

Options trading involves significant risk, and losses can exceed your initial investment. Always consult a licensed financial professional before making investment decisions. OptiView does not provide financial advice; all figures on this page are descriptive statistics, not recommendations.